Mentoring Gender, Selecting Sex
By Osagie Obasogie,
Boston Globe
| 08. 08. 2005
It's a boy! It's a girl! Until the 1970s, these words welcomed virtually every child into the world. In less than one generation, however, new reproductive technologies have shifted this announcement from the delivery room to the obstetricians' office; ultrasounds and amniocenteses now allow expecting parents to choose their nursery walls' paint color months before giving birth.
The science and business of sex identification took yet another quantum leap forward this past week with the Pregnancystore.com's release of the Baby Gender Mentor Home DNA Gender Testing Kit. Now, a woman can know her child's sex shortly after she discovers her pregnancy. As soon as five weeks after conception, she can prick her finger, FedEx a blood sample to Acu-Gen Biolab in Lowell, MA, and have the sex of her sprouting embryo emailed to her faster than Netflix can send her next movie.
An unequivocal good, many say. What's more harmless than learning whether to buy dolls or trucks for the toy chest?
Ultrasounds and amniocenteses cannot accurately determine a fetus' sex until at least four months into pregnancy and sometimes...
Related Articles
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Jason Kehe, Wired | 04.11.2024
God help the babies! Or, absent God, a fertility startup called Orchid. It offers prospective parents a fantastical choice: Have a regular baby or have an Orchid baby. A regular baby might grow up and get cancer. Or be born...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...